At Worldwide, our sickle cell programs are built around the target patient profile. Our site networks reach deeply into high-prevalence communities, our team brings experience from more than 160 cell and gene therapy trials, and one long-standing sponsor partnership has progressed through two FDA approvals over more than a decade. The result is stronger enrollment and retention among patient populations that many sponsors struggle to access and engage.
We’ll connect you with the right classical hematology development team.
Why Sickle Cell Programs Demand Specialized Support
We combine site networks aligned to documented disease prevalence, extensive cell and gene therapy delivery experience, and operational strategies designed around the practical realities of study participation, helping our partners de-risk enrollment and strengthen retention throughout long and complex programs.
Sickle cell disease predominantly affects historically marginalized communities where mistrust of clinical research, limited transportation, financial burden and caregiving responsibilities all sit between an eligible patient and a study visit.
Recent FDA approvals have altered the competitive landscape for recruitment, as patients increasingly compare participation in disease-modifying clinical trials with the availability of potentially curative gene therapies.
Multinational sickle cell studies span substantial variation in healthcare infrastructure, access to standard care, and socioeconomic conditions. Without proactive planning at the protocol design stage, these differences can influence study conduct and ultimately affect data consistency.

Partnership & Approach
One sickle cell partnership began with bioanalytical work in 2013 and has run through accelerated approval, pediatric label expansion and a change of ownership, with Worldwide still on the program. When a sickle cell program grows, we grow with it: Phase I-IV international delivery across pediatric, adolescent and adult populations, with the same senior team carrying the study knowledge forward.
Sickle cell is our largest classical hematology block, with seven programs spanning Phases II-IV and a decade of continuous partnership behind two FDA approvals.
Bioanalytical Methods Validated Across 35 Studies
Worldwide built the bioanalytical foundation for a sickle cell program from the ground up, developing and validating the methods that carried it through to accelerated approval in adults and patients 12 and older.

A Decade of SCD Partnership Through Two FDA Approvals
Continuous partnership with the same sponsor through accelerated adult approval, pediatric label expansion to children over four, and a change of ownership, spanning Phase II international, Phase IV adolescent, adult and pediatric studies and a rescue Phase III pediatric program.

Cell & Gene Therapy Trials Supported
Delivery across hematology, oncology, and rare disease, including the CRISPR-based, ex-vivo and in-vivo gene editing approaches now reshaping sickle cell treatment.

Why Worldwide for Sickle Cell Disease Trials
Extended screening windows, remote consenting, and travel and reimbursement support are built into the operational plan from day one, alongside culturally sensitive patient mobility coordination that accounts for local referral pathways and community trust.
More than 160 cell and gene therapy trials, including autologous cell therapy managed from patient coordination through manufacturing and administration, with the cold chain logistics and chain of identity documentation these programs require.
Transcranial Doppler flow-velocity ranges in eligibility criteria, formulation palatability and dosing instructions in pediatric cohorts, and the screen-failure drivers that show up most often, worked through before the protocol is final.
Frequently Asked Questions
We have answered the questions sponsors ask most often about sickle cell disease clinical development. If yours isn’t here, our classical hematology team is happy to help.
Sickle cell is our largest classical hematology block, with seven programs spanning Phase II-IV, alongside early-phase dose-finding and cell and gene therapy work. Site selection is built around documented disease prevalence in sub-Saharan Africa, India, Latin America and other high-prevalence regions, with enrollment strategies designed for the communities where patients live rather than adapted from traditional trial geographies.
Enrollment starts with the barriers those communities face. Extended screening windows, remote consenting, and travel and reimbursement support go into the operational plan from day one. Patient advocacy partnerships and investigator networks are engaged early, with patient mobility coordination that accounts for local referral pathways, transportation realities and community trust. Worldwide is a member of the Sickle Cell Disease Coalition and the ASH Research Collaborative.
The recent approval of multiple gene therapies for sickle cell disease has shifted patient expectations, with many weighing a potentially curative option. Patient advocacy partnerships and community-level engagement help sponsors reach patients who are still deciding, including those ineligible for gene therapy and those in regions where access remains limited.
Multinational sickle cell trials run across regions with significant differences in healthcare infrastructure, standard-of-care access and socioeconomic conditions, all of which reach data quality if they are not planned for. Site networks are built around documented disease prevalence in sub-Saharan Africa, India and Latin America, regulatory oversight is adjusted at country level, and local cultural and logistical realities go into operational planning from protocol design forward.
Worldwide has supported more than 160 cell and gene therapy trials across hematology, oncology, and rare disease, including ex-vivo and in-vivo gene editing programs. For sickle cell that means managing the autologous cell therapy process from patient coordination through manufacturing and administration, with cold chain logistics, chain of identity documentation and proactive site monitoring built in.
Transcranial Doppler flow-velocity ranges belong in the eligibility criteria, formulation palatability, and dosing instructions decide pediatric compliance, and the most common screen-failure drivers are predictable: prior vaso-occlusive crisis, out-of-range hemoglobin, normal TCD, palatability of the investigational product, and study fatigue when patients roll into an open-label extension. Worldwide works these through before the protocol is final rather than after screening opens.
Sickle cell programs run long, and relationships built with sites, communities and patients over that time are not easily replaced. The same senior scientific and medical leadership stays with a program through database lock, supported by formal succession planning and knowledge-management processes. CRA turnover across the immunology and inflammation franchise runs at 9.5% against an industry average closer to 25%.